VERTEX PHARMACEUTICALS INC / MA Quarterly Other Liabilities, Noncurrent in USD from Q4 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly Other Liabilities, Noncurrent history and growth rate from Q4 2010 to Q2 2024.
  • Vertex Pharmaceuticals Inc / Ma Other Liabilities, Noncurrent for the quarter ending June 30, 2024 was $877M, a 15.5% increase year-over-year.
Other Liabilities, Noncurrent, Quarterly (USD)
Other Liabilities, Noncurrent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $877M +$118M +15.5% Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $854M +$127M +17.5% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $878M +$192M +28% Dec 31, 2023 10-Q 2024-08-02
Q3 2023 $869M +$754M +651% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $759M +$644M +558% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $727M +$609M +519% Mar 31, 2023 10-Q 2023-05-02
Q4 2022 $686M +$383M +126% Dec 31, 2022 10-K 2024-02-15
Q3 2022 $116M +$7.23M +6.66% Sep 30, 2022 10-Q 2022-10-28
Q2 2022 $115M +$7.71M +7.16% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 $117M +$11.1M +10.5% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $303M +$195M +180% Dec 31, 2021 10-K 2023-02-10
Q3 2021 $108M -$320M -74.7% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 $108M -$81.4M -43.1% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 $106M -$75.5M -41.5% Mar 31, 2021 10-Q 2021-04-30
Q4 2020 $108M +$9.37M +9.47% Dec 31, 2020 10-K 2022-02-09
Q3 2020 $429M +$421M +5507% Sep 30, 2020 10-Q 2020-10-30
Q2 2020 $189M +$181M +2260% Jun 30, 2020 10-Q 2020-07-31
Q1 2020 $182M +$176M +2931% Mar 31, 2020 10-Q 2020-05-01
Q4 2019 $99M -$9.83M -9.03% Dec 31, 2019 10-K 2021-02-11
Q3 2019 $7.64M -$18.7M -70.9% Sep 30, 2019 10-Q 2019-10-31
Q2 2019 $8.01M -$17.6M -68.7% Jun 30, 2019 10-Q 2019-08-01
Q1 2019 $6M -$21.5M -78.2% Mar 31, 2019 10-Q 2019-05-01
Q4 2018 $109M +$81.1M +292% Dec 31, 2018 10-K 2020-02-13
Q3 2018 $26.3M +$268K +1.03% Sep 30, 2018 10-Q 2018-10-25
Q2 2018 $25.6M +$370K +1.47% Jun 30, 2018 10-Q 2018-07-26
Q1 2018 $27.5M -$1.01M -3.53% Mar 31, 2018 10-Q 2018-04-27
Q4 2017 $27.8M -$925K -3.22% Dec 31, 2017 10-K 2019-02-13
Q3 2017 $26M -$4.5M -14.7% Sep 30, 2017 10-Q 2017-10-30
Q2 2017 $25.2M -$5.43M -17.7% Jun 30, 2017 10-Q 2017-07-28
Q1 2017 $28.5M -$3.36M -10.5% Mar 31, 2017 10-Q 2017-04-28
Q4 2016 $28.7M -$3.08M -9.69% Dec 31, 2016 10-K 2018-02-15
Q3 2016 $30.5M -$4.47M -12.8% Sep 30, 2016 10-Q 2016-10-31
Q2 2016 $30.6M -$10.6M -25.7% Jun 30, 2016 10-Q 2016-08-01
Q1 2016 $31.8M -$874K -2.67% Mar 31, 2016 10-Q 2016-05-03
Q4 2015 $31.8M +$10.1M +46.4% Dec 31, 2015 10-K 2017-02-23
Q3 2015 $35M +$19M +119% Sep 30, 2015 10-Q 2015-10-30
Q2 2015 $41.3M +$25.6M +163% Jun 30, 2015 10-Q 2015-08-04
Q1 2015 $32.7M +$20.7M +172% Mar 31, 2015 10-Q 2015-05-04
Q4 2014 $21.7M +$10.1M +87.3% Dec 31, 2014 10-K 2016-02-16
Q3 2014 $16M +$5.17M +47.9% Sep 30, 2014 10-Q 2014-11-06
Q2 2014 $15.7M -$383K -2.39% Jun 30, 2014 10-Q 2014-07-31
Q1 2014 $12M -$4.65M -27.9% Mar 31, 2014 10-Q 2014-05-05
Q4 2013 $11.6M -$2.31M -16.6% Dec 31, 2013 10-K 2015-02-13
Q3 2013 $10.8M -$18M -62.5% Sep 30, 2013 10-Q 2013-11-07
Q2 2013 $16M -$12M -42.7% Jun 30, 2013 10-Q 2013-08-02
Q1 2013 $16.7M +$5.79M +53.2% Mar 31, 2013 10-Q 2013-05-08
Q4 2012 $13.9M +$6.62M +90.8% Dec 31, 2012 10-K 2014-02-11
Q3 2012 $28.7M +$20.9M +266% Sep 30, 2012 10-Q 2012-11-06
Q2 2012 $28M +$21.8M +349% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 $10.9M Mar 31, 2012 10-Q 2012-05-10
Q4 2011 $7.29M +$5.02M +222% Dec 31, 2011 10-K 2013-03-01
Q3 2011 $7.85M Sep 30, 2011 10-Q 2011-11-03
Q2 2011 $6.23M Jun 30, 2011 10-Q 2011-08-09
Q4 2010 $2.27M Dec 31, 2010 10-K 2012-02-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.